Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC
Single-arm,Multi-center,Phase II Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Mutation-positive Patients With Advanded NSCLC
Sponsor: Guangdong Provincial People's Hospital
A PHASE2 clinical study on Metastatic Non-small Cell Lung Cancer, this trial is ongoing. The trial is conducted by Guangdong Provincial People's Hospital and has accumulated 10 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Mar 2019 — Jan 2021 [monthly]
Recruiting PHASE2
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE2
-
Jul 2018 — Feb 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Guangdong Provincial People's Hospital
- Hangzhou ACEA Pharmaceutical Research Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China , Fuzhou, China , Guangzhou, China , Hangzhou, China , Jinan, China , Nanning, China and 6 more locations